<DOC>
	<DOCNO>NCT00709956</DOCNO>
	<brief_summary>Patients symptomatic idiopathic pulmonary arterial hypertension ( IPAH ) , familial pulmonary arterial hypertension ( FPAH ) pulmonary hypertension associate Human immunodeficiency virus ( HIV ) drugs/toxins New York Heart Association ( NYHA ) functional class II IV baseline , naive PAH treatment currently treat stable dose either bosentan , ambrisentan sildenafil enrol PROWESS 15 study . This randomized , double blind , placebo-controlled , crossover , single-dose study determine whether single inhale dose iloprost use power 15 disc improves exercise capacity compare placebo patient pulmonary arterial hypertension ( PAH ) .</brief_summary>
	<brief_title>Iloprost Power 15 Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Iloprost</mesh_term>
	<criteria>Signed informed consent prior initiation study mandate procedure , Patients symptomatic idiopathic , familial pulmonary arterial hypertension pulmonary hypertension associate human immunodeficiency virus ( HIV ) drugs/toxins NYHA functional class II IV . Women childbearing potential must negative urine pregnancy test must use adequate method contraception study 28 day discontinuation study drug . Pulmonary arterial hypertension relate condition specify inclusion criterion , Pulmonary arterial hypertension associate significant venous capillary involvement ( Pulmonary capillary wedge pressure ( PCWP ) &gt; 15 mmHg ) , Known pulmonary venoocclusive disease , pulmonary capillary hemangiomatosis , Moderate severe obstructive lung disease : forced expiratory volume 1 second/forced vital capacity ( FEV1/FVC ) &lt; 70 % FEV1 &lt; 65 % predict value bronchodilator administration , Moderate severe restrictive lung disease : total lung capacity ( TLC ) &lt; 60 % predict value , Pregnant breastfeed woman , Systemic hypertension ( systolic blood pressure &gt; 160 mmHg diastolic blood pressure &gt; 100 mmHg repeat measurement ) , Systolic blood pressure &lt; 95 mmHg , Moderate severe hepatic impairment , i.e. , ChildPugh Class B C , Chronic renal insufficiency define serum creatinine &gt; 2.5 mg/dL ( 221 Î¼mol/L ) ongoing dialysis , Clinically relevant bleed disorder active bleeding , For patient monotherapy , contraindication bosentan , ambrisentan , sildenafil , accord product label , Known hypersensitivity iloprost excipients .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Ventavis</keyword>
	<keyword>iloprost</keyword>
	<keyword>inhale treatment</keyword>
	<keyword>pulmonary arterial hypertension</keyword>
</DOC>